Genital infection by herpes simplex virus (HSV) produces a variety of clinical manifestations, patient presentations and management problems which differ in their severity and complexity. In the UK the currently available data for the incidence of genital HSV have been provided predominantly by', the KC60 returns from diagnoses made in genitou.rJj1ary (GU) medicine clinics. The increasing availabilitY and recent publication of the first results, using HSV type-specific anti" body tests within GU and non-GU patient populations, provide a tool to monitor trends in the epidemiology of HSV. It is, however, important to understand that the sexual behaviour which leads to this infection is variable and not necessarily general.
Introduction
Attempts to better the management of individuals with genital herpes have concentrated on improving the clinical diagnosis, improving the laboratory facilities for detecting herpes simplex virus (HSV), and defining clear guidelines for providing newly diagnosed patients with prompt antiviral therapy, counselling, support and followup (Jeffries et et., 1994) . Restricting the study mainly to patients with symptoms and signs that are obvious to genitourinary (GU) physicians may, however, give a misleading view of trends in the epidemiology and management of genital herpes across the wider population.
This review will concentrate on three key and interrelated issues in the management of genital herpes. First, the analysis of the available figures for trends in the number of new cases and recurrences of HSV reported by GU clinics via the KC60 reporting system is considered. In the light of developments in the available type-specific serological tests, the ways in which these can best be applied to provide a meaningful picture of the pattern of HSV infection in the UK will be discussed.
Secondly, it is clear that serological tests identify more individuals as being infected by HSV-2 than previously diagnosed. This test has been proposed as potentially useful to identify HSV-2-positive individuals, particularly in general practice (Corey, 1994) . The potential benefits and drawbacks of this will be discussed. Within this context the issue of the management of genital herpes within the GU clinic or general practice, and how best to facilitate better communication, will be explored.
Finally, there is increasing evidence for asymptomatic shedding of HSV in individuals receiving suppressive doses of aciclovir therapy. With the availability of new compounds such as famciclovir or valaciclovir which may be evaluated and used in this context, it is important to consider what information is given to patients concerning the risks of asymptomatic transmission whilst on suppressive therapies.
In considering these problems new data will be reviewed; however, the need to adhere to the strict principle of ensuring net benefit to the patient by an intended intervention will be reinforced. To ensure that a new test or therapy will be in the best interests of the patient, it is important that the full effects of initiating new approaches be fully worked through with a clear assessment of the effects on a patient's quality of life and their sexual partner's future health.
Is the incidence of genital HSV increasing in the UK?
The only source of annual data on reported cases of genital herpes in the UK is provided by the KC60 reporting system on new cases at National Health Service GU medicine clinics. The most recent report (Department of Health, 1994) of 1993-94 data demonstrates a continued increase in the number of cases of both first-attack and recurrent episodes in men and women (Table 1) . Overall, there was an increase of 6% on 1992-93 evidence, with the proportion attributable to recurrent episodes increasing from 34% in 1988-89 to 43% of the total for 1993-94. There has been much debate as to whether or not this increase in reported presentations by patients with recurrent episodes represents a real change in disease pattern. Alternatively, it could be explained by the increased public awareness, media reports and advertisements by clinics that GU medicine services can provide sympathetic counselling, support, antiviral therapies and new drug trials for the management of the problem. Importantly, the KC60 figures do not differentiate between patients who attend a single clinic and those who may seek help with their problem by attending more than one clinic. This, therefore, adds uncertainty to the figures.
The number of first-attack cases is based on the patient's history and does not differentiate between 'primary' and 'non-primary' episodes. The proportion of firstattack cases has continued to rise, showing a 5% increase over the past year. The increase has been most marked in women, who now account for more than 58% of first presentations. The extent to which patients present outside of genitourinary medicine clinics is hard to know precisely, but from a recent survey (M. Whitaker, General Practitioner, and P. Woolley, GU Physician, University Hospital of South Manchester, personal communication) of over 1000 general practitioners, it is estimated that the majority do manage at least two cases of first-episode genital herpes each year, and that only about a quarter of the total are seen. This constitutes a significant number of diagnosed cases, the management of which does not appear in Department of Health returns, nor have they previously been subject to clinical audit or evaluation; hopefully this situation may change. , 1988-89 to 1993-94 In summary, the general consensus is that there has been a real increase in the workload attributable to genital HSV in GU medicine clinics and that an increasing number of people have come forward with first-episode disease. The advent of type-specific serological tests (Ashley et al., 1988) does offer the possibility of screening individuals in GU clinics, or in the wider population on a sequential basis, to identify trends in the number of those serologically positive and, thus, infected by HSV-2. By removing the primary reliance for collecting figures on clinical disease, it will be possible to gain a more accurate picture of the number of individuals infected by HSV 72as well as an indication of how many develop symptoms and signs that are diagnosed as genital herpes.
Serological type-specific HSV-2 antibody test data
A recent paper by Cowan et al. (1994) was the first publication of serological data using type-specific antibodies from the UK. Their data clearly showed that amongst GU medicine clinic attenders, homosexual men (27.1%) and women (24.5%) had higher levels of HSV-2 seroprevalence than heterosexual men (17.3%). In contrast, the figures for GU clinic attenders were much greater than samples taken from blood donors, with seroprevalence rates of only 3.2% in males and 12.4% in females, respectively. As stated above, only sequential studies using sufficient samples to identify trends in both HSV-1 and f:jSV-2 will provide data to assist in the validation of the KC60 reports. Along with such anonymously collected studies, it would be helpful in this study also to collect demographic sexual behaviour to try to link the trends more closely.
Setting aside the epidemiological issues, there is a major clinical opportunity with the advent of type-specific HSV-2 antibody tests. In the study of Cowan et al. (1994) , only 32.1% of the clinic attenders who had antibodies to HSV-2 had a history of genital herpes; this figure was only 19% amongst the blood donors. What, if anything, is to be done about these findings? Those who take the view that this represents a serious under-diagnosis of HSV-2 infection might be moved to conduct named testing of individuals within a community practice or GU setting, and to 
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Clearly the issue of confidentiality is raised. Many general practitioners refer to this as being a barrier for effective shared care. Attempts to break the barrier may come from the development of clearer guidelines with statements of confidentiality from general practices, as well as utilizing audit and its confidential and anonymous approach. This will enable general practitioners to hear details of the management of their patients without them being so identified. Such an approach could be a prelude to establishing arrangements for 'out-of-hours' and 'difficult cases' care. The ultimate goal should be a jointly authored leaflet which should reflect the available services and would hopefully inform the patient of the choice of where to present to receive optimal care. Asymptomatic shedding -what information should be given to the patient about antiviral therapy?
Asymptomatic shedding and asymptomatic transmission of genital herpes have been well described (Barton et al., 1986) . Recently, cases have been reported of positive viral detection in patients on continuous suppressive doses of aciclovir therapy. Bowman et al. (1990) identified seven individuals on suppressive aciclovir therapy from whom asymptomatic positive viral cultures were obtained. Unfortunately, no data were available from this study of viral sensitivity to aciclovir, nor of serum levels of aciclovir. Despite this, it is clear that multiple-site isolation from such a number of patients receiving aciclovir therapy is a cause for concern. What is not known is the level to which this virus is transmissible to sexual contacts.
Recently, Wald et al. (34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, 4-7 October 1994) presented data on sub-clinical shedding of HSV in 34 women receiving 400 mg bd of either aciclovir or placebo in a controlled cross-over study. Whilst on placebo, sub-clinical shedding occurred in 25 of 34 women (74%) and on 115 out of 1656 study days (6.9%). This compared to sub-clinical shedding in 5 of 34 women (15%) on therapy, affecting only 6 out of 1825 study days (0.3%).
These data create a dilemma for the practising clinician. In the clinical situation one is often faced with an individual who is psychologically traumatized by the prospect of asymptomatic shedding and may be starting suppressive therapy in order to start, or feel able to continue with, a sexual relationship. What should be said to this individual? In terms of patient information, it would seem that honesty should lead the physician to tell the individual that on anyone day there is a 0.3% chance of them shedding HSV and, hence, potentially being infectious. This then raises the issues of the use of barrier contraception or avoidance of genital contact, and begs rrespective of the author's bias (as a GU medicine physician), it is important to approach this question by stating that it should not matter who or where the individual is seen, but, more importantly, how they are managed. Clear priorities for the management Ofpeople with genital herpes are summarized in Table 2 . It seems likely that many general practitioners would be unable to provide the completeness of this approach. However, many general practitioners are consulted by patients with genital ulceration, and thus, they have a pivotal role in advising patients about the management of their condition.
Similarly, it is clear that, outside major cities, GU medicine clinics do not necessarily have open hours throughout every working day and may not have on-call facilities. Hence, there is an opportunity for general practitioners and GU medicine physicians to agree common guidelines for the management of patients presenting with suspected genital herpes, both in and out of hours. This will ensure that the patient has the' correct care, as well as providing the general practitioner with access to information from the GU physician.
inform those who test positive of their result. These individuals could then be counselled and advised to return for repeated examinations if asymptomatic, or to report any symptomatic genital conditions to enable virological culture for HSV. Such an approach has been described (Corey, 1994) ; the study reports that, on follow-up of persons identified in a family health clinic as being HSV-2 seropositive, 75% had clinical or cultural evidence of genital herpes on subsequent testing. The report gives no account of the psychological effects which knowledge of diagnosis had on the individuals or their partners, and provides no data on whether or not such an approach is likely to have any effect on asymptomatic transmissions by encouraging people to practice safer sex when infectious. Further studies and evaluations of psychological, virological and sociological effects of such an approach are essential to allow the proper evaluation of the clinical use of HSV type-specific antibody tests.
On the other hand, if the patient is not told, and there is a case of transmission to a partner whilst on therapy, what would be the medico-legal position? The availability of new drugs, such as famciclovir or valaciclovir, for suppression of HSV raises many issues, ranging from the need to collect safety data comparable to those of aciclovir, to examining the cost benefit of new dosing regimes. In addition, it also raises the question of whether or not, in a patient information sheet for example, telling patients who have previously been on aciclovir that there has been a chance of asymptomatic transmission which may be improved by the new drug could lead to problems in trust about information honesty between doctors, counsellors and patients with frequently recurrent genital herpes. Equally, physicians should be careful not to mislead patients, causing patients without frequent or distressing recurrences to believe that asymptomatic shedding and its avoidance are a prime goal for commencing suppressive therapy. Or should they?
Conclusion 1i
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In summary, clinicians are familiar with the scenario of being asked for help by the patient who is depressed by frequent recurrences of genital herpes, worried about asymptomatic shedding and in no regular relationship. There is a clear goal for therapy in this context to reduce anxiety and psychosexual morbidity, to offer antiviral treatment and to inform the patient about the data on the real and imagined effects of genital HSV on fertility, neoplasia and transmission etc. With the new possibility of detecting cases of HSV-2 serologically, and if we are to try and reduce asymptomatic shedding and, by implication, possible transmission of infection, and if we are to shift the focus of care away from the GU clinics and into the community, we must first be very sure that we do each of these things in the best interests of the patients. If it is not in the patients' best interests, we must continue to concentrate on what we do well in the right context until the consequences of new approaches have been properly evaluated.
